Transparency Market Research

Haemophilus Infections Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

Transparency Market Research ( includes new market research report "Haemophilus Infections Market" to its huge collection of research reports.


Albany, NY -- (SBWIRE) -- 10/30/2014 -- Haemophilus is a group of bacteria that causes different types of illness such as breathing, bone and joint disorders and nervous system disorders. Among all the strains of Haemophilus, H infleunzae type b (Hib) is one of the most common types of infecton causing bacteria. The bacteria is also known as Bacillus Influenzae of Pfeiffer’s bacillus and it is a gram negative, facultatively, ccobacillary, anaerobic bacteria. This strain of bacterium belongs to the Pasteurellaceae family and was first isolated in 1892 during influenza pandemic. Some strains of the H. infleunzae posses a capsule of polysaccharide and on the basis of different biochemical properties of capsule these strains are classified into 6 different subtypes. Among all the strains of Haemophilus, H infleunzae type b (Hib) is the most virulent strain that is responsible for invasive infections. However, there are some strains of Haemophilus that have no capsule and can be termed as non encapsulated or nontypeable H.infleunzae. This strain of bacteria accounts for more than 95% of the infections occurring due to Haemophilus influenza in adults and children. H. infleunzae is also responsible for wide range of invasive and localized infections which can range from mild ear infection to other sever infections like blood stream infections. This strain can cause cellulitis, meningitis, epiglottis, urinary tract infections, septic arthritis, cervical adenitis, endocartis, osteomyelitis and glossitis. Infection caused by non encapsulated H.infleunzae strain includes sinusitis, pneumonia, bronchitis, otitis media and mucosal infections.

Browse the full Haemophilus Infections Market Report with TOC

Hib is a communicable disease and is spread through saliva or mucus. Most of the infections are found to communicate through sneezing or coughing. Thus, for the prevention of influenza infection, vaccination is one of the most common modes of treatment recommended. Thus, children under age of 5 are the most common victim for influenza who haven’t been vaccinated before. According to the WHO in 2000, Hib infections were responsible for cause of approximately 3 million cases of serious infections such as meningitis and pneumonia across the globe. Likewise, the infection also caused 386,000 deaths in young children worldwide. Thus, routine immunization against Haemophilus infection is used in over 100 countries. Additionally, diagnostic tests such as bacterial gram staining, blood cell counts, cerebrospinal fluid studies and others are the major laboratory testing studies performed. Similarly, computed tomography, chest radiography, echocardiography and lateral neck radiography are some of the imaging studies performed to confirm the infection. However, immunization or vaccination remains the major treatment for the prevention of Hib infections. Thus, most of the companies have their drug candidates in the pipeline and are expected to launch in the future.

Rising incidences of Haemophilus Influenzae infection is one of the major causes for the growth of this market. In Japan every year more than 450 children, under the age of 5 years are affected by Hib meningitis. Similarly in the United States the overall incidence of Hib meningitis in children aged 0 years to 4 years 40 to 50 per 10,000. Thus, overall increasing incidences of Haemophilus influezae infection is luring many manufacturers to enter in this market. For, instance HibTITER a first conjugate vaccine proved to be successful in reducing the incidences of H.influenzae. Currently, Nuron Biotech has entered into partnership with Mitsubishi Corporation for the development of single antigen and conjugate vaccine against Hib infection for the Japanese market.

Takeda Pharmaceuticals, GlaxoSmith Kline Plc, Sanofi, Inc., Novartis AG, Biological E. Limited, Panacea Biotech Limited, Zydus Cadila Healthcare Limited, Nuron Biotech, Inc., Sinovac Biotech Limited and others are some of the major players operating in this segment.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends.

Geographies analyzed under this research report include:

- North America
- Asia Pacific
- Europe
- Rest of the World

This report provides comprehensive analysis of:

- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Read More Reports on Pharmaceutical Market:

About Transparency Market Research
Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Enquiry before Buying

Latest Upcoming Reports

Contact Us:

Sheela AK
Corporate Office:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States.

Tel: 518-618-1030

Browse market research blog: